Cardiac disease in pregnancy and arrhythmias: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Cardiac disease in pregnancy}} | {{Cardiac disease in pregnancy}} | ||
{{CMG}}; {{AOEIC}} {{CZ}} | {{CMG}}; {{AOEIC}} {{CZ}} | ||
| Line 4: | Line 5: | ||
==Overview== | ==Overview== | ||
Although underlying reasons remain unclear, if a woman has a prior history of [[arrhythmias]], the risk of recurrent arrhythmias may increase during pregnancy.<ref> Tawam M, Levine J, Mendelson M, Goldberger J, Dyer A, Kadish A. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 1993; 72: 838-40.</ref> <ref>Brodsky M, Doria R, Allen B, Sato D, Thomas G, Sada M. New-onset ventricular tachycardia during pregnancy. Am Heart J 1992; 123: 933-41.</ref> <ref name="Chow">Chow T, Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol 1998; 82 (4A): 58I - 62I. </ref> Unfortunately drugs that are effective in the management of arrhythmias such as [[amiodarone]] can present a hazard to the fetus during pregnancy. | Although underlying reasons remain unclear, if a woman has a prior history of [[arrhythmias]], the risk of recurrent arrhythmias may increase during pregnancy.<ref> Tawam M, Levine J, Mendelson M, Goldberger J, Dyer A, Kadish A. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 1993; 72: 838-40.</ref> <ref>Brodsky M, Doria R, Allen B, Sato D, Thomas G, Sada M. New-onset ventricular tachycardia during pregnancy. Am Heart J 1992; 123: 933-41.</ref> <ref name="Chow">Chow T, Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol 1998; 82 (4A): 58I - 62I. </ref> Unfortunately drugs that are effective in the management of arrhythmias such as [[amiodarone]] can present a hazard to the fetus during pregnancy. | ||
==Arrythmias== | |||
==Supraventricular | ===Supraventricular Tachycardia During Pregnancy=== | ||
*If there is hemodynamic compromise, the patient can be treated with DC [[cardioversion]]. | *If there is hemodynamic compromise, the patient can be treated with DC [[cardioversion]]. | ||
*A rapid narrow complex rhythm suggestive of [[AV nodal re-entry tachycardia]] ([[AVNRT]]) can be treated emergently with IV [[adenosine]] which has a very short half life. | *A rapid narrow complex rhythm suggestive of [[AV nodal re-entry tachycardia]] ([[AVNRT]]) can be treated emergently with IV [[adenosine]] which has a very short half life. | ||
*[[Lopressor]] is a mainstay of prevention of [[SVT]] in the setting of pregnancy. [[Atenolol]] and [[propranolol]] should be avoided given the risk of [[intrauterine growth retardation]]. [[Calcium channel blockade]] would be second line therapy. [[Sotalol]] and [[flecainide]] can be used in refractory cases. Ablation can be performed in refractory cases. Given the risk of fetal hypo/hyperthyroidism with amiodarone, this agent is not recommended. | *[[Lopressor]] is a mainstay of prevention of [[SVT]] in the setting of pregnancy. [[Atenolol]] and [[propranolol]] should be avoided given the risk of [[intrauterine growth retardation]]. [[Calcium channel blockade]] would be second line therapy. [[Sotalol]] and [[flecainide]] can be used in refractory cases. Ablation can be performed in refractory cases. Given the risk of fetal hypo/hyperthyroidism with amiodarone, this agent is not recommended. | ||
==Ventricular Tachycardia During Pregnancy== | ===Ventricular Tachycardia During Pregnancy=== | ||
===Acute VT=== | ====Acute VT==== | ||
*If there is hemodynamic compromise, DC [[cardioversion]] is recommended. | *If there is hemodynamic compromise, DC [[cardioversion]] is recommended. | ||
*If the patient is hemodynamically stable with symptoms, then [[lidocaine]], [[procainamide]] or as a last resort, [[amiodarone]] are recommended. | *If the patient is hemodynamically stable with symptoms, then [[lidocaine]], [[procainamide]] or as a last resort, [[amiodarone]] are recommended. | ||
===Recurrent VT=== | ====Recurrent VT==== | ||
*Ascertaining and directing the appropriate therapy to the underlying cause of the VT is critical such as [[right ventricular outflow tract tachycardia]], [[Long QT Syndrome]] (treat with [[beta-blockers]]). | *Ascertaining and directing the appropriate therapy to the underlying cause of the VT is critical such as [[right ventricular outflow tract tachycardia]], [[Long QT Syndrome]] (treat with [[beta-blockers]]). | ||
*The following drugs are pregnancy category C drugs, and can be administered if the benefits outweigh the risks: | *The following drugs are pregnancy category C drugs, and can be administered if the benefits outweigh the risks: | ||
| Line 22: | Line 23: | ||
*[[Amiodarone]] is a [[pregnancy category]] D drug. Amiodarone has been associated with fetal [[hypothyroidism]] and [[hyperthyroidism]], fetal bradycardia, [[intrauterine growth retardation]]. The expert consensus is that amiodarone use should be restricted to the management of refractory maternal or fetal tachyarrhythmias. Given the long half life of amiodarone, if a woman intends to become pregnant, the drug should be discontinued several months before conception. [[Thyroid function tests]] in the neonate are recommended if the mother is administered [[amiodarone]]. | *[[Amiodarone]] is a [[pregnancy category]] D drug. Amiodarone has been associated with fetal [[hypothyroidism]] and [[hyperthyroidism]], fetal bradycardia, [[intrauterine growth retardation]]. The expert consensus is that amiodarone use should be restricted to the management of refractory maternal or fetal tachyarrhythmias. Given the long half life of amiodarone, if a woman intends to become pregnant, the drug should be discontinued several months before conception. [[Thyroid function tests]] in the neonate are recommended if the mother is administered [[amiodarone]]. | ||
==Anti-arrhythmic Drugs to Avoid During the Pregnancy== | ===Anti-arrhythmic Drugs to Avoid During the Pregnancy=== | ||
* [[Amiodarone]]<ref name="Onuigbo"> Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. South Med J 1998; 91: 1153-5.</ref>: | * [[Amiodarone]]<ref name="Onuigbo"> Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. South Med J 1998; 91: 1153-5.</ref>: | ||
| Line 33: | Line 34: | ||
:* [[Hypoglycemia]] in the newborn | :* [[Hypoglycemia]] in the newborn | ||
==Anti-arrhythmic Drugs to Avoid During Lactation== | ===Anti-arrhythmic Drugs to Avoid During Lactation=== | ||
* [[Amiodarone]]<ref name="Onuigbo"> Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. South Med J 1998; 91: 1153-5.</ref>: | * [[Amiodarone]]<ref name="Onuigbo"> Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. South Med J 1998; 91: 1153-5.</ref>: | ||
| Line 47: | Line 48: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[CME Category::Cardiology]] | |||
[[Category:Disease]] | |||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category: | [[Category:Obstetrics]] | ||
Latest revision as of 20:47, 29 July 2020
|
Cardiac disease in pregnancy Microchapters |
|
Diagnosis |
|---|
|
Catheterization: |
|
Treatment |
|
Special Scenarios:
|
|
Cardiac disease in pregnancy and arrhythmias On the Web |
|
American Roentgen Ray Society Images of Cardiac disease in pregnancy and arrhythmias |
|
Directions to Hospitals Treating Cardiac disease in pregnancy |
|
Risk calculators and risk factors for Cardiac disease in pregnancy and arrhythmias |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Although underlying reasons remain unclear, if a woman has a prior history of arrhythmias, the risk of recurrent arrhythmias may increase during pregnancy.[1] [2] [3] Unfortunately drugs that are effective in the management of arrhythmias such as amiodarone can present a hazard to the fetus during pregnancy.
Arrythmias
Supraventricular Tachycardia During Pregnancy
- If there is hemodynamic compromise, the patient can be treated with DC cardioversion.
- A rapid narrow complex rhythm suggestive of AV nodal re-entry tachycardia (AVNRT) can be treated emergently with IV adenosine which has a very short half life.
- Lopressor is a mainstay of prevention of SVT in the setting of pregnancy. Atenolol and propranolol should be avoided given the risk of intrauterine growth retardation. Calcium channel blockade would be second line therapy. Sotalol and flecainide can be used in refractory cases. Ablation can be performed in refractory cases. Given the risk of fetal hypo/hyperthyroidism with amiodarone, this agent is not recommended.
Ventricular Tachycardia During Pregnancy
Acute VT
- If there is hemodynamic compromise, DC cardioversion is recommended.
- If the patient is hemodynamically stable with symptoms, then lidocaine, procainamide or as a last resort, amiodarone are recommended.
Recurrent VT
- Ascertaining and directing the appropriate therapy to the underlying cause of the VT is critical such as right ventricular outflow tract tachycardia, Long QT Syndrome (treat with beta-blockers).
- The following drugs are pregnancy category C drugs, and can be administered if the benefits outweigh the risks:
- Amiodarone is a pregnancy category D drug. Amiodarone has been associated with fetal hypothyroidism and hyperthyroidism, fetal bradycardia, intrauterine growth retardation. The expert consensus is that amiodarone use should be restricted to the management of refractory maternal or fetal tachyarrhythmias. Given the long half life of amiodarone, if a woman intends to become pregnant, the drug should be discontinued several months before conception. Thyroid function tests in the neonate are recommended if the mother is administered amiodarone.
Anti-arrhythmic Drugs to Avoid During the Pregnancy
- Significant fetal abnormalities.
- Neonatal hypothyroidism
- Fetal goiter
- Fetal growth retardation
- Propranolol and atenolol[5] [6]:
- Intrauterine growth restriction
- Hypoglycemia in the newborn
Anti-arrhythmic Drugs to Avoid During Lactation
- Secreted in breast milk
- It becomes concentrated in breast milk. Infants receive much larger doses.
- Neonatal bradycardia
- Neonatal hypoglycemia
Related Chapters
References
- ↑ Tawam M, Levine J, Mendelson M, Goldberger J, Dyer A, Kadish A. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 1993; 72: 838-40.
- ↑ Brodsky M, Doria R, Allen B, Sato D, Thomas G, Sada M. New-onset ventricular tachycardia during pregnancy. Am Heart J 1992; 123: 933-41.
- ↑ Chow T, Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol 1998; 82 (4A): 58I - 62I.
- ↑ 4.0 4.1 4.2 Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. South Med J 1998; 91: 1153-5.
- ↑ Eliahou HE, Silverberg DS, Reisin E, Romem I, Mashiach S, Serr DM. Propranolol for the treatment of hypertension in pregnancy. Br J Obstet Gynaecol 1978;85:431-6.
- ↑ Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541-7.